Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Robert P Jones

Showing results (51-60 of 66) with videos related to

Pageof 7
Sort By:
Nature Cancer|March 13, 2024
Author Correction: Efferocytosis reprograms the tumor microenvironment to promote pancreatic cancer liver metastasisYuliana Astuti, Meirion Raymant, Valeria Quaranta, et al.
Archives of Toxicology|April 4, 2016
Mechanistic evaluation of primary human hepatocyte culture using global proteomic analysis reveals a selective dedifferentiation profileJames A Heslop, Cliff Rowe, Joanne Walsh, et al.
Nature Cancer|February 14, 2024
Efferocytosis reprograms the tumor microenvironment to promote pancreatic cancer liver metastasisYuliana Astuti, Meirion Raymant, Valeria Quaranta, et al.
Digestive Surgery|April 16, 2025
Current Practice in the Treatment of Colorectal Liver Metastases by Irreversible Electroporation: An International Questionnaire Survey (LIVERMET-IRE-Q)Harry V M Spiers, Saurabh Jamdar, Santhalingam Jegatheeswaran, et al.
Toxicological Sciences : an Official Journal of the Society of Toxicology|July 11, 2015
Comparative Proteomic Characterization of 4 Human Liver-Derived Single Cell Culture Models Reveals Significant Variation in the Capacity for Drug Disposition, Bioactivation, and DetoxicationRowena L C Sison-Young, Dimitra Mitsa, Rosalind E Jenkins, et al.
BJS Open|May 22, 2022
The dilemma of the disappeared colorectal liver metastasis: systematic review of reviews and evidence gap mapAhmed Nassar, Sorin Cimpean, Amir Abdelhamid, et al.
The British Journal of Surgery|September 28, 2022
SARS-CoV-2 in the abdomen or pelvis: SAFE SURGERY studyDale Vimalachandran, Robert P Jones, Ed Dickson, et al.
Cancers|July 14, 2023
Impact of COVID-19 on 1-Year Survival Outcomes in Hepatocellular Carcinoma: A Multicenter Cohort StudyShuell De Souza, Jeffrey Kahol de Jong, Ylenia Perone, et al.
Oncotarget|June 23, 2018
The Nrf2 inhibitor brusatol is a potent antitumour agent in an orthotopic mouse model of colorectal cancerJonathan P Evans, Boleslaw K Winiarski, Paul A Sutton, et al.
Oncotarget|February 19, 2019
Correction: The Nrf2 inhibitor brusatol is a potent antitumour agent in an orthotopic mouse model of colorectal cancerJonathan P Evans, Boleslaw K Winiarski, Paul A Sutton, et al.
Pageof 7

Showing results (51-60 of 66) with videos related to

Sort By:
Pageof 7
Nature Cancer|March 13, 2024
Author Correction: Efferocytosis reprograms the tumor microenvironment to promote pancreatic cancer liver metastasisYuliana Astuti, Meirion Raymant, Valeria Quaranta, et al.
Archives of Toxicology|April 4, 2016
Mechanistic evaluation of primary human hepatocyte culture using global proteomic analysis reveals a selective dedifferentiation profileJames A Heslop, Cliff Rowe, Joanne Walsh, et al.
Nature Cancer|February 14, 2024
Efferocytosis reprograms the tumor microenvironment to promote pancreatic cancer liver metastasisYuliana Astuti, Meirion Raymant, Valeria Quaranta, et al.
Digestive Surgery|April 16, 2025
Current Practice in the Treatment of Colorectal Liver Metastases by Irreversible Electroporation: An International Questionnaire Survey (LIVERMET-IRE-Q)Harry V M Spiers, Saurabh Jamdar, Santhalingam Jegatheeswaran, et al.
Toxicological Sciences : an Official Journal of the Society of Toxicology|July 11, 2015
Comparative Proteomic Characterization of 4 Human Liver-Derived Single Cell Culture Models Reveals Significant Variation in the Capacity for Drug Disposition, Bioactivation, and DetoxicationRowena L C Sison-Young, Dimitra Mitsa, Rosalind E Jenkins, et al.
BJS Open|May 22, 2022
The dilemma of the disappeared colorectal liver metastasis: systematic review of reviews and evidence gap mapAhmed Nassar, Sorin Cimpean, Amir Abdelhamid, et al.
The British Journal of Surgery|September 28, 2022
SARS-CoV-2 in the abdomen or pelvis: SAFE SURGERY studyDale Vimalachandran, Robert P Jones, Ed Dickson, et al.
Cancers|July 14, 2023
Impact of COVID-19 on 1-Year Survival Outcomes in Hepatocellular Carcinoma: A Multicenter Cohort StudyShuell De Souza, Jeffrey Kahol de Jong, Ylenia Perone, et al.
Oncotarget|June 23, 2018
The Nrf2 inhibitor brusatol is a potent antitumour agent in an orthotopic mouse model of colorectal cancerJonathan P Evans, Boleslaw K Winiarski, Paul A Sutton, et al.
Oncotarget|February 19, 2019
Correction: The Nrf2 inhibitor brusatol is a potent antitumour agent in an orthotopic mouse model of colorectal cancerJonathan P Evans, Boleslaw K Winiarski, Paul A Sutton, et al.
Pageof 7